Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

被引：0
|
作者：
Deangelo, Daniel J. [1 ]
Chen, Ying [2 ]
Cassaday, Ryan D. [3 ,4 ]
Hibma, Jennifer [2 ]
Yang, Derek Z. [2 ]
Garrett, May [2 ]
Zhang, Fan [5 ]
Dimitrov, Svetoslav H. [6 ]
Vandendries, Erik [7 ]
Kantarjian, Hagop M. [8 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[2] Pfizer, San Diego, CA USA
[3] Univ Washington, Seattle, WA USA
[4] Fred Hutchinson Canc Ctr, Seattle, WA USA
[5] Pfizer, Shanghai, Peoples R China
[6] Pfizer, New York, NY USA
[7] Pfizer Inc, Cambridge, MA USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-194244
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：732 / 733
页数：2
相关论文
共 50 条
  • [31] The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study
    Ozcan, Muhit
    Cassaday, Ryan D.
    Singh, Pawan
    Zarzycka, Ewa
    Zhang, Xin
    Negre, Eric
    Vandendries, Erik
    Altuntas, Fevzi
    BLOOD, 2021, 138
  • [32] Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease
    Kayser, Sabine
    Sartor, Chiara
    Luskin, Marlise R.
    Webster, Jonathan
    Giglio, Fabio
    Panitz, Nydia
    Brunner, Andrew M.
    Fante, Matthias
    Lutz, Christoph
    Wolff, Daniel
    Ho, Anthony D.
    Levis, Mark
    Schlenk, Richard F.
    Papayannidis, Cristina
    BLOOD, 2021, 138
  • [33] Inotuzumab Ozogamicin Salvage Monotherapy for the Treatment of Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia
    Darcin, Tahir
    Yigenoglu, Tugce Nur
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Merdin, Alparslan
    Yildiz, Jale
    Ulu, Bahar Uncu
    Tetik, Aysegul
    Iskender, Dicle
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S192 - S193
  • [34] BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN COLOMBIA
    Arciniegas, J.
    Sossa, C.
    Nakandakari, M. L.
    Reyes Sanchez, J. M.
    VALUE IN HEALTH, 2023, 26 (06) : S88 - S88
  • [35] Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
    May Garrett
    Ana Ruiz-Garcia
    Kourosh Parivar
    Brian Hee
    Joseph Boni
    Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46 : 211 - 222
  • [36] PROGNOSTIC IMPLICATIONS OF PRETREATMENT CYTOGENETICS IN ADULTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN
    Jabbour, E.
    Advani, A.
    Stelljes, M.
    Stock, W.
    Liedtke, M.
    Goekbuget, N.
    Martinelli, G.
    O'Brien, S.
    White, J. Liang
    Wang, T.
    Paccagnella, M. L.
    Sleight, B.
    Vandendries, E.
    DeAngelo, D. J.
    Kantarjian, H. M.
    HAEMATOLOGICA, 2017, 102 : 198 - 198
  • [37] Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia
    Dahl, Jenny
    Marx, Kayleigh
    Jabbour, Elias
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (04) : 329 - 334
  • [38] Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia Reply
    Kantarjian, Hagop M.
    Vandendries, Erik
    Advani, Anjali S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2100 - 2101
  • [39] Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
    Tvito, Ariella
    Rowe, Jacob M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (12) : 1557 - 1564
  • [40] Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
    Ueda, Tomoaki
    Fukushima, Kentaro
    Kusakabe, Shinsuke
    Yoshida, Koki
    Suga, Makiko
    Nakai, Ritsuko
    Koike, Midori
    Hino, Akihisa
    Akuta, Keigo
    Toda, Jun
    Nagate, Yasuhiro
    Doi, Yukiko
    Fujita, Jiro
    Yokota, Takafumi
    Hosen, Naoki
    LEUKEMIA RESEARCH REPORTS, 2022, 17
12345